title: [The neurotoxicity of pyridinium metabolites of haloperidol].
abstract: Haloperydol is a butyrophenone, typical neuroleptic agent characterized as a high antipsychotics effects in the treatment of schizophrenia and in palliative care to alleviation many syndromes, such as naursea, vomiting and delirium. Clinical problems occurs during and after administration of the drug are side effects, particularly extrapyrramidal symptoms (EPS). The neurotoxicity of haloperydol may be initiated by the cationic metabolites of haloperydol, HPP+, RHPP+, formed by oxidation and reduction pathways. These metabolites are transported by human organic cation transporters (hOCT) to several brain structures for exapmle, in substantia nigra, striatum, caudate nucleus, hippocampus. After reaching the dopaminergic neurons inhibits mitochondrial complex I, evidence for free radical involvement, thus leading to neurodegeneration.
authors.affiliation: Katedra i Zakład Chemii Leków, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Górska
authors.affiliation: Katedra i Zakład Chemii Leków, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu.
authors.forename: Michał
authors.initials: M
authors.lastname: Marszałł
authors.affiliation: Katedra i Zakład Farmakodynamiki i Farmakologii Molekularnej.
authors.forename: Anna
authors.initials: A
authors.lastname: Sloderbach
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology*; D001711:Biotransformation; D001921:Brain / Q000187:drug effects*; D003693:Delirium / Q000188:drug therapy; D006220:Haloperidol / Q000009:adverse effects* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009325:Nausea / Q000188:drug therapy; D019636:Neurodegenerative Diseases / Q000139:chemically induced*; D020258:Neurotoxicity Syndromes; D012559:Schizophrenia / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D006220:Haloperidol